Abstract:Lecithin:cholesterol acyltransferase (LCAT) exhibits α-activity on high-density and β-activity on low-density lipoproteins. However, the molecular determinants governing LCAT activation by different apolipoproteins remain elusive. Uncovering these determinants would offer the opportunity to design and explore advanced therapies against dyslipidemias. Here, we have conducted coarse-grained and all-atom molecular dynamics simulations of LCAT with nanodiscs made with α-helical amphiphilic peptides either derived from apolipoproteins A1 and E (apoA1 and apoE) or apoA1 mimetic peptide 22A that was optimized to activate LCAT. This study aims to explore what drives the binding of peptides to our previously identified interaction site in LCAT. We hypothesized that this approach could be used to screen for binding sites of LCAT in different apolipoproteins and would provide insights to differently localized LCAT activities. Our screening approach was able to discriminate apoA1 helixes 4, 6, and 7 as key contributors to the interaction with LCAT supporting the previous research data. The simulations provided detailed molecular determinants driving the interaction with LCAT: the formation of hydrogen bonds or salt bridges between peptides E4 or D4 and LCAT S236 or K238 residues. Additionally, salt bridging between R7 and D73 was observed, depending on the availability of R7. Expanding our investigation to diverse plasma proteins, we detected novel LCAT binding helixes in apoL1, apoB100, and serum amyloid A. Our findings suggest that the same binding determinants, involving E4 or D4 -S236 and R7-D73 interactions, influence LCAT β-activity on low-density lipoproteins, where apoE and or apoB100 are hypothesized to interact with LCAT. Atherosclerotic cardiovascular disease is caused by the accumulation of cholesterol in arteries. A developing class of therapies against it attempt to promote the efficiency of high-density lipoprotein (HDL), which removes cholesterol from peripheral cells. Importantly, this includes cholesterol-laden macrophages, also known as foam cells, present in atherosclerotic lesions. In this context, one strategy focuses on improving the cholesterol carrying capacity of HDL by improving the enzymatic activity of lecithin:cholesterol acyltransferase (LCAT). Although LCAT remodels HDL to accept more cholesterol, it also remodels low-density lipoprotein (LDL), which has an opposite effect to HDL. In other words, LDL brings cholesterol to peripheral cells. We hypothesize that this may be part of the reason why LCAT activation hasn't shown clinical success thus far. In order to investigate this, we must selectively inhibit LCAT's activity on LDL, which in turn requires us to know which amino acids take part in the LCAT-HDL and LCAT-LDL interactions. In this article, we've used molecular dynamics simulations to reveal these amino acids. This information will be useful in the optimization of LCAT and HDL based therapies against atherosclerosis as well as in the design of HDL-like drug delivery systems whose properties are affected by LCAT.

Ligand-receptor interaction in the specific targeting of biomimetic peptide nanoparticles to lysophosphatidylcholine

Elucidating the Binding Mechanism of LPA Species and Analogs in an LPA4 Receptor Homology Model

The choice of targets and ligands for site-specific delivery of nanomedicine to atherosclerosis

A preliminary study on the biomimetic drug delivery system targeting atherosclerotic lesions

Effects of Shear Stress on the Binding of Atherosclerosis Targeting Nanoparticles to Activated Endothelial Cells

Red Blood Cell Membrane Spontaneously Coated Nanoprodrug Based on Phosphatidylserine for Antiatherosclerosis Applications

Nanoparticle Ligand Exchange and Its Effects at the Nanoparticle-Cell Membrane Interface

Pro-efferocytosis biomimetic nanocomplexes for targeted atherosclerosis therapy through promoting macrophage re-polarization and inhibiting senescence

Pro-efferocytic macrophage membrane biomimetic nanoparticles for the synergistic treatment of atherosclerosis via competition effect

In silico studies of interactions of peptide-conjugated cholesterol metabolites and betulinic acid with EGFR, LDR, and N-terminal fragment of CCKA receptors

Advances in the treatment of atherosclerosis with ligand-modified nanocarriers

The Study of Liposome Surface Ligand Density on Its Targeting Efficiency in Vivo

Biomimetic Liposomes Hybrid with Platelet Membranes for Targeted Therapy of Atherosclerosis

Nanoparticle Functionalization with Platelet Membrane Enables Multifactored Biological Targeting and Detection of Atherosclerosis

Novel peptide inhibitors targeting CD40 and CD40L interaction: A potential for atherosclerosis therapy

Biomimetic-Coated Nanoplatform with Lipid-Specific Imaging and ROS Responsiveness for Atherosclerosis-Targeted Theranostics

Brain-targeted Drug Delivery by in Vivo Functionalized Liposome with Stable D-peptide Ligand.

Therapeutic potentials of peptide-derived nanoformulations in atherosclerosis: present status and future directions

Biomimetic Nanotherapies: Red Blood Cell Based Core–Shell Structured Nanocomplexes for Atherosclerosis Management

Systematic evaluation of lecithin:Cholesterol acyltransferase binding sites in apolipoproteins via peptide based nanodiscs: Regulatory role of charged residues at positions 4 and 7

Recent progress in biomimetic nanomedicines based on versatile targeting strategy for atherosclerosis therapy